Loading
A phase 1/2 trial of Docetaxel, Toripalimab, Carboplatin, Niraparib and Lenvatinib in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06682780 by LaNova Medicines Limited, with 320 participants planned, started 2025-09-17 and due to reach its primary completion in 2028-12-25. Interventions recorded: LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib and Lenvatinib.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.